Sysco Corp saw a 2.7% year-on-year sales increase to $19.38 billion in Q3 FY24. With U.S. Foodservice sales up 3.4% and International Foodservice sales up 4.5%.
Biodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual MeetingBiodexa Pharmaceuticals
Harmony Biosciences expands its late-stage CNS pipeline with the acquisition of Epygenix Therapeutics, bolstering its rare epilepsy offerings. Harmony's Q1 performance shows robust growth, with adjusted EPS surpassing expectations.
GE Healthcare reports first-quarter sales of $4.6 billion, with net income of $374 million. Imaging and ultrasound segment revenues down, but pharmaceutical diagnostics up. Despite challenges in China, CEO remains optimistic, reaffirming guidance for 2024.
RenovaroCube, wholly owned subsidiary of Renovaro, Inc. (NASDAQ:RENB), a company at the forefront of AI-driven healthcare innovation, proudly unveils Flamingo, a potentially groundbreaking multi-cancer detection model
Pfizer's Q1 earnings report expects EPS of 49 cents and $13.09 billion in revenues. Stock has declined 34.61% YoY and -10.94% YTD due to COVID-19 revenue decrease. Technical analysis shows bearish trend with potential for further downside.